Gene Editing Therapies

product pipeline / R&D affecting expense

“The following table summarizes our research and development expenses for the three months ended March 31, 2026 and 2025, together with the changes in those items in dollars (in thousands): Three Months Ended March 31, Period to Period 2026 2025 Change External research and development expenses $ 21,450 $ 17,852 $ 3,598 Employee-related expenses 14,991 19,735 (4,744 ) Facility expenses 22,234 23,959 (1,725 ) Stock-based compensation expenses 7,854 9,732 (1,878 ) Other expenses 385 408 (23 ) Sublicense and license fees 1,660 798 862 Total research and development expenses $ 68,574 $ 72,484 $ (3,910 ) The decrease of approximately $3.9 million was primarily attributable to a decrease in employee-related costs, including stock-based compensation expenses, offset by an increase in external research and development expenses.”

CRSP 10-Q

credit / rates affecting interest expense

“The increase was primarily due to non-cash interest expense associated with the liability related to the sale of future royalties and the Credit Facility, partially offset by higher income from increased investment yields.”

ARWR 10-K

credit / rates

“Cash provided by financing activities of $781.0 million was primarily due to $681.3 million net proceeds from the issuance of convertible note, $116.6 million in net proceeds from a follow-on common stock offering, $46.8 million in net proceeds from the issuance of common stock under the Company's at-the-market equity offering program, $100.0 million proceeds from issuance of pre-funded warrants and $10.1 million proceeds from the exercise of stock options, partially offset by partial repayment of the credit facility of $84.5 million, purchase of the Capped Calls of $47.9 million, and dividends paid to noncontrolling shareholders of $41.5 million (See Note 6 — Stockholders’ Equity of”

ARWR 10-Q